Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Sarcoma 4Osteosarcoma 2Neoplasms 2Chondrosarcoma 2Uterine Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Adenoviridae Infections 1

Interventions

Ifosfamide 5Filgrastim 5Doxorubicin 5Gemcitabine 4Docetaxel 4Radiotherapy 3Proton Therapy 3Carboplatin 3regorafenib 2ivosidenib 2enasidenib 2belinostat 2Sunitinib 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Immune Checkpoint Inhibitors 2HhAntag691 2Fluorouracil 2Etoposide 2Epirubicin 2Cyclophosphamide 2Cisplatin 2Chemotherapy, Adjuvant 2Celecoxib 2Bevacizumab 2venetoclax 1toripalimab 1temsirolimus 1tazemetostat 1tanespimycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Chondrosarcoma × Immune Checkpoint Inhibitors × Sarcoma × Clear all
NCT04673942 2024-10-26

BETA-PRIME

EpicentRx, Inc.

Phase 2 Recruiting
140 enrolled
Sarcoma

Adenoviridae Infections, Chondrosarcoma, Neoplasms, Sarcoma

NCT05193188 2023-02-16

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
70 enrolled
Sarcoma

Chondrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡